AbCellera Biologics (ABCL) Company Report

AbCellera Biologics is transitioning from a platform-focused company to a clinical-stage biotech, having completed investments in downstream capabilities, including a clinical manufacturing facility in Vancouver, to support its internal pipeline.
The company has shifted its strategy to prioritize internal programs, stopping active pursuit of new partnerships while maintaining existing commitments and selectively considering new ones that align with internal criteria.
Its most advanced internal program, ABCL635, is a non-hormonal treatment for moderate to severe hot flashes, currently in a Phase I trial to assess efficacy signals and target engagement.
AbCellera also has ABCL575 for atopic dermatitis, which it aims to partner after Phase I data, and ABCL688 for autoimmune conditions, with an IND or Canadian equivalent CTA submission expected in mid-2026.
The company maintains a strong capital position with approximately $680 million in available liquidity at the end of the last quarter, providing a runway of well over three years for continued investment in its internal pipeline.

1 day ago

Transcript

AbCellera Biologics Discusses Transition to Clinical Stage and Pipeline at Piper Sandler Conference

ABCL

New Projects/Investments

AbCellera Biologics has transitioned from a platform-focused company to a clinical-stage biotech, having completed investments to build end-to-end integrated capabilities from target assessment to clinical manufacturing.
The company is advancing its internal pipeline, with ABCL635 (non-hormonal treatment for hot flashes) as its most advanced program, currently in a Phase 1 trial. ABCL688, targeting autoimmune conditions, is expected to have an IND/CTA submission in mid-2026.
AbCellera has stopped actively seeking new partnerships to prioritize independent drug development, though it remains committed to existing partners and may selectively accept new programs.
The company maintains a strong capital position with approximately $680 million in available liquidity as of the end of the last quarter, providing over three years of runway for internal pipeline investments.

1 day ago

Transcript

AbCellera Details Transition to Clinical-Stage Biotech and Pipeline Programs

ABCL

New Projects/Investments

Guidance Update

AbCellera (ABCL) has transitioned from a platform-focused company to a clinical-stage biotech, having completed investments in downstream capabilities for translational biology, manufacturing, and clinical development, making it end-to-end integrated.
The company has stopped actively seeking new partnerships to prioritize its internal pipeline but remains committed to existing collaborations and may selectively accept new programs that align with its strategic focus.
ABCL's most advanced internal program, ABCL 635, is in a Phase 1 trial for the non-hormonal treatment of moderate to severe hot flashes (vasomotor symptoms), targeting NK3R, with early efficacy signals expected from the study.
ABCL 575, an OX40 ligand blocker for atopic dermatitis, is also in Phase 1, with the company seeking to confirm its safety and pharmacokinetic/pharmacodynamic profile to potentially partner the program for further development.
AbCellera maintains a strong capital position with approximately $680 million in available liquidity as of the end of the last quarter, providing over three years of funding for its internal pipeline, which includes ABCL 688 (autoimmune conditions) and over 20 other programs.

1 day ago

Transcript

AbCellera Biologics Discusses Clinical Pipeline Transition and Financial Position

ABCL

New Projects/Investments

Guidance Update

AbCellera Biologics has completed its transition to developing its own clinical assets, with its first two wholly-owned assets moving into the clinic in 2025.
The lead wholly-owned asset, ABCL635, an antibody against the NK3R receptor for hot flashes associated with VMS, is in Phase 1 trials, with proof-of-concept data expected by mid-2026. This asset is differentiated as a first-in-class monoclonal antibody with a potential monthly injectable dosing regimen.
Other pipeline assets include ABCL575, an OX40 ligand antagonist in Phase 1, and ABCL688, a new IND candidate targeting GPCRs, which entered IND-enabling studies in Q3 2025.
The company reports a strong balance sheet with over CAD 500 million in cash and equivalents and just under CAD 200 million in available liquidity from government funding, totaling around CAD 700 million in liquidity, sufficient for at least the next three years.

Nov 13, 2025, 1:00 PM

Transcript

AbCellera Provides Update on Clinical Pipeline and Financial Position

ABCL

New Projects/Investments

Guidance Update

AbCellera has transitioned to developing its own clinical assets, with two wholly-owned assets, ABCL635 and ABCL575, entering the clinic in Q2 2025, and a third, ABCL688, in IND enabling studies in Q3 2025. The company expects first readouts for its wholly-owned assets in 2026.
ABCL635, an antibody for hot flashes associated with VMS, is a first-in-class monoclonal antibody with potential for monthly subcutaneous injection. Phase 1 includes a proof of concept study in post-menopausal women, with biomarker data and proof of concept results expected by mid-2026.
As of its Q3 earnings, AbCellera reported the following liquidity information :

Metric	Q3 2025
Cash and Equivalents ($USD Millions)	Over $500
Available Liquidity from Government Spending ($USD Millions)	Under $200
Total Available Liquidity ($USD Millions)	Around $700
Liquidity Runway (Years)	At least 3

Nov 13, 2025, 1:00 PM

Transcript

AbCellera Biologics Details Transition to Wholly-Owned Assets and Pipeline Progress

ABCL

New Projects/Investments

Product Launch

Guidance Update

AbCellera Biologics has completed its strategic transition to developing wholly-owned clinical assets, with ABCL635 and ABCL575 entering the clinic in Q2 2025 and ABCL688 in IND-enabling studies in Q3 2025.
The lead asset, ABCL635, a first-in-class monoclonal antibody for hot flashes associated with menopause, targets a $6 billion addressable market. It aims to differentiate through a monthly subcutaneous injection and potentially superior safety/efficacy compared to existing daily oral small molecules.
Phase 1 trials for ABCL635 are supported by Canadian government funding (45% cost coverage), with a proof of concept study starting in early 2026 and initial data expected by mid-2026.
The company reports a strong financial position with over $500 million in cash and equivalents and under $200 million in government liquidity, providing at least three years of liquidity.

Nov 13, 2025, 1:00 PM

Transcript

Prelude Therapeutics Reports Q3 2025 Financial Results and Provides Corporate Update

ABCL

Earnings

Guidance Update

New Projects/Investments

Prelude Therapeutics reported a net loss of $19.7 million (or $0.26 per share) on $6.5 million in revenue for the third quarter ended September 30, 2025.
The company ended Q3 2025 with $58.2 million in cash, cash equivalents, restricted cash, and marketable securities, and anticipates a cash runway into 2027, including $60 million received from Incyte in November 2025.
Prelude expects to file an Investigational New Drug (IND) application for its JAK2V617F JH2 inhibitor program in Q1 2026 and for its oral KAT6A selective degrader program in mid-2026.
The JAK2V617F inhibitor program is subject to an exclusive option agreement with Incyte announced in November 2025, and the company has amended and expanded its DAC collaboration with AbCellera Biologics.

Nov 12, 2025, 12:01 PM

Press Release

AbCellera Reports Q3 2025 Financial Results and Clinical Pipeline Progress

ABCL

Earnings

New Projects/Investments

Management Change

AbCellera reported Q3 2025 revenue of $9 million and a net loss of approximately $57 million, leading to a loss of $0.19 per share.
The company maintains a strong liquidity position, ending Q3 2025 with approximately $680 million in available liquidity, comprising $520 million in cash and cash equivalents and $160 million in committed government funding.
Phase I clinical trials for ABCL 635 and ABCL 575 are progressing as planned, with readouts anticipated next year.
AbCellera expects to advance at least one additional development candidate into IND enabling studies by year-end, marking the fourth in its pipeline.
Dr. Sarah Nunberg was appointed as Chief Medical Officer during the quarter.

Nov 6, 2025, 10:00 PM

Transcript

ABCL Reports Q3 2025 Financials and Clinical Pipeline Progress

ABCL

Earnings

New Projects/Investments

Management Change

AbCellera reported $9 million in revenue for Q3 2025, leading to a net loss of approximately $57 million and a loss of $0.19 per share.
The company ended Q3 2025 with approximately $680 million in available liquidity, comprising $520 million in cash and cash equivalents and $160 million in committed government funding.
Phase I clinical trials for ABCL 635 and ABCL 575 are progressing as planned and are on track for readouts next year, with the company also expecting to advance at least one more development candidate into IND enabling studies by year-end.
Research and development expenses increased to $55 million in Q3 2025, reflecting a strategic focus on internal programs, and the company has substantially completed its platform and clinical manufacturing facility investments.

Nov 6, 2025, 10:00 PM

Transcript

AbCellera Reports Q3 2025 Financial Results and Clinical Pipeline Progress

ABCL

Earnings

New Projects/Investments

Management Change

AbCellera (ABCL) reported a net loss of $57.1 million and ($0.19) per share for Q3 2025.
As of September 30, 2025, the company had approximately $680 million in available liquidity, which includes $520 million in total cash, cash equivalents, and marketable securities, and $160 million in total available government funding.
In Q3 2025, ABCL initiated Phase 1 clinical trials for ABCL635 in June 2025 and ABCL575 in July 2025, and nominated ABCL688 as an additional development candidate for CTA-enabling studies.
Revenue for Q3 2025 included $9.0 million from licensing and $8.8 million from research fees, while Research & Development expenses were $55.0 million.

Nov 6, 2025, 10:00 PM

Presentation

Earnings Transcripts

Quarterly earnings call transcripts for AbCellera Biologics.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Carl L.G. Hansen say about margins?What are AbCellera Biologics's strategic priorities?How is AbCellera Biologics positioned vs competitors?How did AbCellera Biologics do last quarter?

Let Fintool AI Agent track AbCellera Biologics's earnings for you

Get instant analysis when filings drop